
price close busi juli
biomed devic servic
encourag look momentum
maintain hold price target
bottom line maintain hold rate post result came slightli
ahead expect overal result encourag pocket
perform stabil us continu apac strength remain cautiou
timelin need overcom oper issu prevent share
loss regain market share necessari compon acceler top-lin
growth unlock sharehold valu think guidanc
appropri conserv xfx sale growth commentari impact
oper ineffici remedi effort emphas time
invest requir turnaround
sum current valuat ep estim surpris
long-term investor start opportunist build posit next six
month particularli given manag provid enough forward inform
start piec togeth mosaic howev messag regard timelin
suppli new product turnaround sale momentum increasingli make
feel like late event reiter hold given expect share remain
range-bound upsid top-lin growth target look challeng
supply/manufactur issu weigh margin next month slightli
increas price target use discount peer multipl
top line post revenu cg/street estim
compani continu deal suppli issu result show
sign progress stabil key segment us hips/kne
apac continu strong momentum xfx growth xfx hips/
knee continu benefit weight legaci zimmer product
less affect suppli issu offset growth xfx declin emea
neg impact suppli constraint tender time
manufactur call manag reiter confid formal
respons publicli releas fda observ
compani continu make progress remedi effort appear time
effort remain move target said manag note suppli
impact execut revenu guidanc point continu think
manufactur issu resolv remain cautiou given uncertainti
surround time subsequ cadenc recaptur lost custom
pipelin updat manag reiter expect pipelin product
play import part compani return sustain revenu earn
growth note zimmer highlight recent launch persona trabecular metal
tibia allow zimmer offer full cementless knee persona partial knee system
help fill knee portfolio look forward manag reiter
expect launch persona revis knee tka rosa robot system
view pipelin posit howev expect take
least product materi impact top-lin growth sentiment
manag reiter call
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
zimmer report sale estim
street revenu support strength asia pacif
stabil busi america off-set weak emea addit qualiti
remedi effort manufacturing/suppli issu continu impact
margin due higher product cost includ dual sourc inventori outsid
vendor invest end adjust gross margin came
y/i pro forma oper margin
y/i zimmer report adjust ep compar our/consensu
estim
figur result vs estim consensu
come manag lower report sale growth rang
larg due lower fx tailwind expect
said manag
rais bottom end constant currenc revenu growth rang y/i
growth compar previou guidanc compani becom
confid underli busi pro forma ep expect
reiter rang adjust oper margin reiter
rang compani adjust tax rate expect
rang free cash flow slightli increas rang
 lastli pro-forma ep guidanc unchang
rang
hold unchang target price juli
biomed devic servic
overal performanceactualcg estimatebeat/miss beat/miss consensusbeat/missnet good gross pro-forma oper net revenu productactualcg estimatebeat/miss beat/miss growthnet revenu geographyactualcg estimatebeat/miss beat/miss growthnet number us million zimmer biomet hold
chang estim
made follow chang estim
figur summari chang estim
hold unchang target price juli
biomed devic servic
except ep newold newold newold revenu gross operatin ebitda net zimmer biomet hold
broad large-cap med-tech group current trade mean price-to-earnings multipl
valu zimmer discount large-cap med-tech group given
uncertainti surround remedi suppli issu impact revenu
margin sum slightli increas price target base
price-to-earnings multipl appli pro-forma ep
figur matrix discount rate impli share price target
zimmer biomet
zimmer world-wide leader design develop manufactur market
reconstruct spinal implant trauma relat orthoped surgic product
hold unchang target price juli
biomed devic servic
comp pe multipl price metric use price-to-earnings valuat analysisbroad large-cap medic devic price-to-earnings multipl adjust pro-forma figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
hold unchang target price juli
biomed devic servic
zimmer biomet incom statementcanaccord genuiti kyle except per share good devic gener asset op incom chg chg amort stk incom minor incom ep ep one-tim ep chg share gener oper rate adjust growth growth ep ex compani document canaccord genuiti estim figur pro forma revenu build
hold unchang target price juli
biomed devic servic
zimmer biomet revenu buildcanaccord genuiti kyle euro yen fx impact impact fx growth growth zimmer biomet hold
